Kirby McInerney LLP Reminds Investors of the Lead Plaintiff Deadline in the Class Action Lawsuit Against Vertex Pharmaceuticals, Inc.

Kirby McInerney LLP announced today that a class action lawsuit has been commenced in the United States District Court for the District of Massachusetts on behalf of investors who acquired Vertex Pharmaceuticals, Inc. (“Vertex” or the “Company”) (NASDAQ-GS:VRTX) securities from May 7, 2012 through May 29, 2012. By law, investors have until July 28, 2014 to file a motion to be appointed as lead plaintiff in the investor lawsuit.

The lawsuit charges that the Company made false and misleading public statements concerning two of its drugs, VX-809 and Kalydeco, during the Class Period. Specifically, on May 7, 2012, the Company announced interim data for its second Phase of testing for these products. The Company stated that the tests resulted in 46% of its treatment group experiencing “an absolute improvement” in lung function of five percentage points or more and 30% experiencing absolute improvement of ten percentage points or more. In fact, the Company revealed on May 29, 2012 that the test results had been misread, and that the results of the study were in truth much more modest. When this was revealed, Vertex’s stock price declined from $64.85 to $57.80 per share. Prior to this disclosure, Company insiders reaped nearly $30 million in proceeds from sales of their own stock.

If you acquired Vertex securities during this period and you are interested in learning more about this matter and any rights you might have with respect to these claims, contact Wilona Karnadi or Jess Kelley at securitiescases@kmllp.com, by telephone at (212) 371-6600, or by filling out this form. Please bear in mind that some of these rights may be time-sensitive.

Kirby McInerney LLP is a New York-based plaintiffs’ law firm concentrating in securities, whistleblower, antitrust and consumer litigation. The firm has specialized in complex litigation, including securities class actions, for several decades. Kirby McInerney LLP has repeatedly demonstrated its expertise in this field, and has been recognized by various courts that have appointed the firm to major positions in consolidated and multi-district litigation. The firm’s efforts on behalf of shareholders in securities litigation have resulted in recoveries totaling billions of dollars, and the firm’s achievements and quality of service have been chronicled in numerous published decisions. Additional information about the firm or the claims against Vertex can be found at Kirby McInerney LLP’s website: http://www.kmllp.com.

Contacts:

Kirby McInerney LLP
Wilona Karnadi / Jess Kelley, 212-371-6600
securitiescases@kmllp.com

Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.